At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 39 enrolled

Drug / intervention

Curcumin +1 moredrug

Likely dose

Curcumin 360 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02104752

NCT02104752Phase 2Completed

Compare CT.gov

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

VA Greater Los Angeles Healthcare System·interventional·Posted Apr 4, 2014·Updated May 15, 2019

In Brief

A Phase 2 clinical trial evaluating Curcumin and Placebo for Schizophrenia and 2 related conditions. Completed, enrolled 39 participants across 1 site.

Detailed Summary

The investigators propose to test whether curcumin nanoparticles will improve behavioral measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who are already receiving a stable dose of antipsychotic.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsSchizophrenia, Cognition, Psychosis

CountriesUnited States

CollaboratorsStanley Medical Research Institute, Theravalues, Inc., University of California, Los Angeles

Timeline

Phase 2CompletedFinished

2014201520162017201820192020202120222023202420252026

First PostedApr 2014

Enrollment StartJul 2014

Primary CompletionMay 2016

Study CompletionOct 2017

TodayJul 2026

First PostedApr 4, 2014

Enrollment StartJul 1, 2014

Primary CompletionMay 1, 2016

Study CompletionOct 1, 2017

TodayJul 2, 2026

Enrollment to primary: 1.8 yearsPosted 12.2 years ago

Interventions

Curcumindrug

360 mg/day (divided into twice daily oral doses)

Placebodrug

Inactive, matched placebo ("Sugar Pill")